MYSTIC, Conn. and DUBLIN, March 31, 2011 /PRNewswire/ -- Amarin Corporation plc (Nasdaq :AMRN ), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that Executive Chairman and Chief Executive Officer, Joseph Zakrzewski, will present at 8:40 a.m. EDT on April, 6, 2011 at the 10th Annual Needham Healthcare Conference in New York City. Additionally, Amarin's President, John Thero, will be available at the conference to respond to questions from investors. A live Webcast of the presentation will be available at the following URL:
Amarin Corporation plc is a clinical-stage biopharmaceutical company with expertise in lipid science focused on the treatment of cardiovascular disease. The Company's lead product candidate is AMR101, the active ingredient in which is ethyl-EPA (ethyl icosapentate). On November 29, 2010, the Company reported positive, statistically significant top-line results from the MARINE trial, the first of its Phase 3 clinical trials of AMR101. In the MARINE trial, AMR101 was investigated as a treatment for very high triglycerides (>500 mg/dL). AMR101 is presently being investigated in a second Phase 3 clinical trial, the ANCHOR trial, for the treatment of patients on statin therapy with high triglycerides (e200 and <500mg/dL) with mixed dyslipidemia. The MARINE trial was, and the ANCHOR trial currently is, conducted under Special Protocol Assessment (SPA) agreements with the U.S. Food and Drug Administration (FDA). Amarin also has next-generation lipid candidates under evaluation for preclinical development.
Investor Contact Information:
Stephen D. Schultz
Investor Relations and Corporate Communications
In U.S.: +1 (860) 572-4979 x292
Lee M. Stern
The Trout Group
In U.S.: +1 (646) 378-2922
Media Contact Information:
David Schull or Martina Schwarzkopf, Ph.D.
In U.S.: +1 (212) 845-4271 or +1 (212) 845-4292 (office)
+1 (347) 591-8785 (mobile)
SOURCE Amarin Corporation plc